GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RAY1225

Company
Guangdong Raynovent Biotech Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for RAY1225 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06254261

    A Study of RAY1225 in Participants With Obesity

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 270 participants Est. completion 2025-12-20 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT06893016

    Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 640 participants Est. completion 2026-09-15 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05835752

    The Safety, Tolerability and Pharmacokinetic Study of RAY1225

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 68 participants Est. completion 2024-03-23 1 site Stand-alone
    Other conditions: Obese, Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT06254274

    A Study of RAY1225 in Participants With Type 2 Diabetes

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 210 participants Est. completion 2025-12-20 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06577415

    A Study of RAY1225 in Participants With Impaired Liver Function

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 24 participants Est. completion 2025-11-15 1 site Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT06577428

    A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 48 participants Est. completion 2024-10-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06613763

    A Study of RAY1225 in Participants With Impaired Kidney Function

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 32 participants Est. completion 2025-01-20 1 site Stand-alone
    Other conditions: Kidney Impairment
    View official trial listing →
  • Not yet recruiting NCT NCT07139535

    A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 350 participants Est. completion 2026-12-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07139548

    A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 600 participants Est. completion 2026-12-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07362030

    Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 32 participants Est. completion 2026-03-30 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07460284

    A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants

    Not yet reported Guangdong Raynovent Biotech Co., Ltd 8 participants Est. completion 2026-10-28 1 site Stand-alone
    Other conditions: Basic Science
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.